Seek truth from facts, competitive symbiosis
06
2021-06
Hunan Zhengqing Pharmaceutical Group Co., Ltd. Announcement of Resolutions from the 2020 Annual General Meeting of Shareholders I. Meeting Convening and Attendance Time: June 18, 2021, 9:30 AM Venue: 5th Floor Meeting Room, No. 7 Cai Fu Road, Huaihua High-tech Development Zone, Hunan Method: On-site Convenor: Board of Directors Chairperson: Chairman Wu Feichi A total of 18 shareholders and shareholder representatives attended this general meeting, holding 180,818,025 shares with voting rights, accounting for 88.5191% of the company's total shares. II. Review of Proposals A total of 20 proposals were reviewed at this meeting, all approved with 100% of the voting shares held by the attending shareholders. Specifically: 1. "Company's 2020 Annual Board of Directors' Work Report"; 2. "Company's 2020 Annual Board of Supervisors' Work Report"; 3. "Company's 2020 Annual Audit Report"; 4. "Company's 2020 Annual Financial Settlement and 2021 Annual Financial Budget Report"; 5. "Company's 2020 Annual Profit Distribution Plan"; 6. "Proposal on Appointing the Accounting Firm for 2021"; 7. "Proposal on Confirming the Company's 2020 Daily Related Party Transactions and Estimating 2021 Daily Related Party Transactions" (Related parties Huaihua Dadi Holding Co., Ltd., Hunan Xiangjiang Liyuan Zhenghong Venture Capital Partnership (Limited Partnership), Huaihua High-tech Industrial Investment Partnership (Limited Partnership), Huaihua Mountain Operations Co., Ltd., Wu Feichi, and Huang Yuming abstained from voting on this proposal); 8. "Proposal on Amending the
05
2021-05
Notice of the 2020 Annual General Meeting of Shareholders
Hunan Zhengqing Pharmaceutical Group Co., Ltd.Resolution of the 12th Meeting of the 6th Board of Directorsand Notice of Convening the 2020 Annual Shareholders' MeetingHunan Zhengqing Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") held the 12th Meeting of the 6th Board of Directors on May 27, 2021, at Zhengqing Group, No. 7 Cailu Road, High-tech Zone, Huaihua, Hunan. The meeting notice was delivered to all directors on May 17, 2021, by phone, fax, and other means. Five directors of the Company should have attended the meeting; five directors actually attended and voted. The meeting was chaired by Mr. Wu Feichi, Chairman. The meeting approved proposals such as the "Company's 2020 Annual Board of Directors' Work Report" by vote and submitted them to the Shareholders' Meeting for deliberation.The relevant matters for the Company's 2020 Annual Shareholders' Meeting are hereby notified as follows:1. Meeting Time: 9:30 AM, June 18, 20212. Meeting Venue: Zhengqing Group, No. 7 Cailu Road, High-tech Zone, Huaihua, Hunan3. Convener of the Meeting: The Company's Board of Directors4. Attendees:(1) Directors, Supervisors, and Senior Management of the Company;(2) Shareholders registered as of June 13, 2021;(3) Lawyers hired by the Company and other personnel invited by the Company's Board of Directors.I. Matters for Deliberation at the MeetingThis meeting will deliberate on the following proposals:1. "Company's 2020 Annual Board of Directors' Work Report";2. "Company's 2020 Annual Supervisors' Work Report";3. "Company's 2020 Annual Audit Report";4. "Company's 2020 Annual Financial Final Accounts and 2021 Annual Financial Budget Report";5. "Company's 2020 Annual Profit Distribution Plan";6. "Proposal on Engaging an Accounting Firm for 2021";7. "Proposal on Confirming the Company's 2020 Annual Related Party Transactions and Estimating 2021 Annual Related Party Transactions";8. "Proposal on Amending the
04
2021-04
The board of directors and all directors of the company guarantee that there are no false records, misleading statements, or major omissions in the content of this announcement, and they assume legal responsibility for the truthfulness, accuracy, and completeness of its content.Hunan Zhengqing Pharmaceutical Group Co., Ltd. (hereinafter referred to as “the Company”) has obtained approval from the China Securities Regulatory Commission for its targeted issuance of shares to specific investors (hereinafter referred to as “this targeted issuance”) through the “Approval on the Targeted Issuance of Shares by Hunan Zhengqing Pharmaceutical Group Co., Ltd.” (CSRC Approval [2020] No. 2165), approving the company to issue no more than 134,000,000 new shares in a targeted manner.The Company completed this targeted issuance in April 2021, issuing a total of 134,000,000 RMB ordinary shares to 6 specific investors at an issuance price of RMB 3.5 per share, raising a total of RMB 469,000,000, of which RMB 134,000,000 is newly added registered capital (share capital).According to the results of this targeted issuance and the authorization of the company's general meeting of shareholders, the company has amended relevant clauses in its “Articles of Association.” Article 4 of Chapter 1 has been revised to “The company's registered capital is RMB 204,270,346”; Article 16 of Chapter 3 has been revised to “The company's total shares are 204,270,346 shares.” The company has now completed the industrial and commercial registration procedures for the amendment of its “Articles of Association” and the change in registered capital, and has obtained a new “Business License.” This targeted issuance has been completed according to legal procedures.The company will subsequently handle the registration and custody procedures at Hunan Equity Registration and Management Center Co., Ltd.This announcement is hereby made.Hunan Zhengqing Pharmaceutical Group Co., Ltd.Board of DirectorsApril 23, 2021
08
2020-08
湖南正清制药集团股份有限公司 关于2020年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性称述或重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南正清制药集团股份有限公司（以下简称“公司”）根据《非上市公众公司监督管理办法》等相关法律、法规和规范性文件的规定，公司编制了2020年半年度募集资金的存放和使用情况专项报告。 一、定向发行股票募集资金基本情况 公司2019年7月27日第六届董事会第三次会议、2019年8月12日2019年第二次临时股东大会审议通过了《关于公司2019年第一次股票定向发行方案的议案》。 公司最终向吴飞驰、刘运君发行股票17,964,071股，最终股票发行价格为每股人民币1.67元，最终募集资金总额为3,000.00万元。上述募集资金已于2019年11月13日全部到位，经中审众环会计师事务所（特殊普通合伙）审验并出具了“众环验字(2019)第110005号”《验资报告》。 二、募集资金存放和管理情况 （一）募集资金存放情况 公司按照《募集资金管理制度》的规定，为本次发行设立了募集资金专项账户，专门存放与管理募集资金。账户具体信息如下： 账户名称：湖南正清制药集团股份有限公司 开户行：中国建设银行股份有限公司怀化市分行银建支行 账户：43050172903700000616 （二）募集资金管理情况 公司的《募集资金管理制度》经2019年8月13日第六届董事会第四次会议审议通过。公司对募集资金实行专户存储和管理，并于2019年11月，公司、中国建设银行股份有限公司怀化市分行银建支行、中信建投证券股份有限公司共同签订了《募集资金三方监管协议》、开设了募集资金专项账户，并将募集资金共计30,000,000.00元全部转入公司募集资金专项账户。公司在募集资金使用、监管和责任追究等各方面，严格遵守管理办法，切实保护公司和股东的合法权益。 三、募集资金的实际使用情况 截至2020年6月30日，公司2020年半年度募集资金具体使用情况如下： 项目 金额（元） 一、上期期末募集资金余额 15,906.47 二、利息收入扣除手续费净额 12.06 三、可使用募集资金金额 15,918.53 四、募集资金使用—流动资金使用 15,918.53 五、账户余额 0 截至2020年5月13日，公司将2019年定向发行股票募集的专项资金30,000,000.00元全部使用完毕。 四、募集资金使用及披露中存在的问题 公司本期不存在变更募集资金使用用途的情况，不存在未及时、真实、准确、完整披露募集资金使用的情况。募集资金的存放、使用、管理及披露不存在违法、违规之情形。 四、关于公司募集资金存放与实际使用情况的结论性意见 公司董事会认为，截至2020年6月30日，本次定向发行股票募集资金和募集资金存放与实际使用符合《非上市公众公司监督管理办法》等相关法律、法规和规范性文件的规定，不存在违规存放募集资金的情况，也不存在控股股东、实际控制人或其他关联方占用或转移本次定向发行募集资金的情形。 湖南正清制药集团股份有限公司 董事会 2020年8月27日
Copyright Hunan Zhengqing Pharmaceutical Group Co., Ltd.
Virtual Showroom：
Agent：
OA：
CRM：
在线客服添加返回顶部
右侧在线客服样式 1,2,3 1
图片alt标题设置： Hunan Zhengqing Pharmaceutical Group Co., Ltd.
表单验证提示文本： Please enter correct content!
循环体没有内容时： Updating......
CSS / JS 文件放置地